Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Isabelle R Weir

Showing results (1-10 of 15) with videos related to

Pageof 2
Sort By:
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|July 13, 2021
Treatment Effect Measures for Culture Conversion Endpoints in Phase IIb Tuberculosis Treatment TrialsIsabelle R Weir, Sean Wasserman
Clinical Trials (London, England)|August 4, 2018
Design of non-inferiority randomized trials using the difference in restricted mean survival timesIsabelle R Weir, Ludovic Trinquart
Contemporary Clinical Trials|January 22, 2024
An evaluation of confidence intervals for a cumulative proportion to enable decisions at interim reviews of single-arm trialsIsabelle R Weir, Linda J Harrison
Biostatistics (Oxford, England)|June 9, 2019
Multivariate meta-analysis model for the difference in restricted mean survival timesIsabelle R Weir, Lu Tian, Ludovic Trinquart
Pharmaceutical Statistics|August 4, 2021
Counterfactual mediation analysis in the multistate model framework for surrogate and clinical time-to-event outcomes in randomized controlled trialsIsabelle R Weir, Jennifer R Rider, Ludovic Trinquart
Journal of Clinical Epidemiology|October 10, 2018
Design analysis indicates Potential overestimation of treatment effects in randomized controlled trials supporting Food and Drug Administration cancer drug approvalsEmily M Lord, Isabelle R Weir, Ludovic Trinquart
Research Square|November 21, 2023
Estimands for clinical endpoints in Tuberculosis treatment randomized controlled trials: a retrospective application in a completed trialIsabelle R Weir, Suzanne M Dufault, Patrick Pj Phillips
Trials|March 12, 2024
Estimands for clinical endpoints in tuberculosis treatment randomized controlled trials: a retrospective application in a completed trialIsabelle R Weir, Suzanne M Dufault, Patrick P J Phillips
BMC Medical Research Methodology|May 24, 2025
Summary measures in non-inferiority clinical trials with a time-to-event outcome: an empirical comparison of powerS D Lana Broer, Ian R White, Tim P Morris, et al.
BMC Medical Research Methodology|November 19, 2022
Methods for handling missing data in serially sampled sputum specimens for mycobacterial culture conversion calculationSamantha Malatesta, Isabelle R Weir, Sarah E Weber, et al.
Pageof 2

Showing results (1-10 of 15) with videos related to

Sort By:
Pageof 2
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|July 13, 2021
Treatment Effect Measures for Culture Conversion Endpoints in Phase IIb Tuberculosis Treatment TrialsIsabelle R Weir, Sean Wasserman
Clinical Trials (London, England)|August 4, 2018
Design of non-inferiority randomized trials using the difference in restricted mean survival timesIsabelle R Weir, Ludovic Trinquart
Contemporary Clinical Trials|January 22, 2024
An evaluation of confidence intervals for a cumulative proportion to enable decisions at interim reviews of single-arm trialsIsabelle R Weir, Linda J Harrison
Biostatistics (Oxford, England)|June 9, 2019
Multivariate meta-analysis model for the difference in restricted mean survival timesIsabelle R Weir, Lu Tian, Ludovic Trinquart
Pharmaceutical Statistics|August 4, 2021
Counterfactual mediation analysis in the multistate model framework for surrogate and clinical time-to-event outcomes in randomized controlled trialsIsabelle R Weir, Jennifer R Rider, Ludovic Trinquart
Journal of Clinical Epidemiology|October 10, 2018
Design analysis indicates Potential overestimation of treatment effects in randomized controlled trials supporting Food and Drug Administration cancer drug approvalsEmily M Lord, Isabelle R Weir, Ludovic Trinquart
Research Square|November 21, 2023
Estimands for clinical endpoints in Tuberculosis treatment randomized controlled trials: a retrospective application in a completed trialIsabelle R Weir, Suzanne M Dufault, Patrick Pj Phillips
Trials|March 12, 2024
Estimands for clinical endpoints in tuberculosis treatment randomized controlled trials: a retrospective application in a completed trialIsabelle R Weir, Suzanne M Dufault, Patrick P J Phillips
BMC Medical Research Methodology|May 24, 2025
Summary measures in non-inferiority clinical trials with a time-to-event outcome: an empirical comparison of powerS D Lana Broer, Ian R White, Tim P Morris, et al.
BMC Medical Research Methodology|November 19, 2022
Methods for handling missing data in serially sampled sputum specimens for mycobacterial culture conversion calculationSamantha Malatesta, Isabelle R Weir, Sarah E Weber, et al.
Pageof 2